Aglaia is founded on the principle that the willingness to take risks on the very early stage ventures of today results in opportunities that may grow into the winning companies of tomorrow. As such, we are typically the first provider of capital for startup and early stage companies and a driving force behind product development. We invest in novel tools and technologies as well as components of contemporary drug development.
The number of technological discoveries in the biomedical field is growing exponentially. A deep understanding of the translation of these discoveries into novel products is a prerequisite for success. Aglaia’s focus on oncology is a differentiating asset.
Opportunities may be derived from research centers as well as from corporate spinouts. We select, develop and commercialize promising technologies up to a level where the technology becomes an attractive target for licensing or acquisition by a pharmaceutical biotech company.
Technologies meeting the following criteria are eligible for further evaluation:
We do not ask scientists and entrepreneurs to cover all these topics in detail. We merely seek to discuss these criteria and work together in defining a sound business scenario.
Inthera Bioscience AG expands management team with seasoned professionals and secures €4.7 million second tranche of €9.6 million Series A financing
InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting